1. At a Glance – The Balm That Refuses to Retire
If Indian households had a “default setting,” it would include one thing: a tiny green bottle of Amrutanjan. Headache? Balm. Cold? Balm. Existential crisis after checking your portfolio? Balm again.
Now here’s the twist — this 130+ year old company is still trying to act like a Gen-Z FMCG startup. They’re selling pain balms, sanitary napkins, and electrolyte drinks under one roof. Basically, if life hurts you physically or emotionally, Amrutanjan wants a piece of that revenue.
But here’s the spicy part:
- Q3 FY26 revenue: ₹141 Cr
- PAT: ₹19 Cr
- OPM: ~18%
- Stock down ~22% in 1 year
So the business is growing… but the stock is behaving like it just saw its own medical bill.
And somewhere between a 73% market share in roll-ons and a ₹123 Cr capex on sanitary pads, lies a question:
👉 Is this a boring legacy FMCG quietly compounding… or a confused multi-category experiment?
Let’s investigate.
2. Introduction – From Ayurvedic Balm to FMCG Multiverse
Amrutanjan started in 1893, which means it has survived:
- British Raj
- License Raj
- Your uncle’s “multibagger tips”
And yet, today, it’s trying to reinvent itself.
The company operates in three major segments:
- Pain management (the OG business)
- Women’s hygiene (Comfy)
- Beverages (Electro+)
And here’s the reality:
- 90% of revenue comes from OTC products
- Comfy alone contributes 28% inside OTC
- Beverages are just ~10%
So despite all the diversification drama, this is still fundamentally a pain-relief company with side hustles.
But management has a dream:
👉 ₹1000 Cr revenue by FY28
Current revenue? ~₹488 Cr
So they need to double in ~3–4 years.
Simple question:
👉 Can a balm company suddenly become a growth machine?
3. Business Model – WTF Do They Even Do?
Let’s simplify this like explaining to a lazy investor:
🧴 Core Business: Pain Relief
- Balms, roll-ons, patches
- 73% market share in
